新型含多吡啶Ru-Mn配合物的合成及其抗肿瘤活性  

Synthesis and Antitumor Activity of A Novel Ru-Mn Complex Containing Polypyridine

作　　者：黄莉 耿艺 王慧 熊一萍 张诗琪 王勇[1] HUANG Li;GENG Yi;WANG Hui;XIONG Yiping;ZHANG Shiqi;WANG Yong(Key Laboratory of Drug Synthesis and Optimization,College of Chemical Engineering and Pharmacy,Jingchu University of Technology,Jingmen 448000,China)

机构地区：[1]荆楚理工学院化工与制药学院药物合成与优化湖北省重点实验室,湖北荆门448000

出　　处：《合成化学》2024年第11期1007-1012,共6页Chinese Journal of Synthetic Chemistry

基　　金：湖北省自然科学基金资助项目(2022CFB532);荆门市重点科技计划项目(2024YFZD039);大学生创新创业项目(KC2024011);荆楚理工学院教育教学研究重点项目(JX2023-016)。

摘　　要：多吡啶钌配合物有着较强的生物活性、较低的毒性和较快的代谢速率等优点,被认为是最有潜力的非铂金属抗肿瘤药物。本文以物质的量之比为1∶1的单核化合物[Mn^(Ⅲ)(salen)](ClO_(4))]和K[Ru^(Ⅱ)(L)(CN)_(3)](L=4′-苯基-2,2′∶6′,2”-三联吡啶)作为原料,设计并合成了新型含多吡啶Ru-Mn配合物[Ru^(Ⅱ)(L)(CN)_(3)][Mn^(Ⅲ)(salen)](1),利用元素分析、红外光谱、紫外-可见光谱和X-射线单晶衍射分析对其结构进行表征,并采用CCK8法研究了化合物1的抗肿瘤活性。结果表明:化合物1的单晶结构为正交晶系Pbca空间群,对Hela细胞生长有抑制作用,当其质量浓度为1000μg/mL时,Hela细胞的相对活性降低至65.82%。Polypyridine ruthenium complexes have the advantages of strong biological activity,low toxicity and fast metabolic rate,and are considered as the most potential non-platinum anti-tumor drugs.In this paper,a novel Ru-Mn complex containing polypyridine was designed and synthesized by using mononuclear compound[Mn^(Ⅲ)(salen)](ClO_(4))]and K[Ru^(Ⅱ)(L)(CN)_(3)](L=4′-phenyl-2,2′∶6′,2′′-tripyridine)in a ratio of 1∶1.The results showed that the single crystal structure of compound 1 was orthorhombic Pbca space group,which inhibited the growth of Hela cells.When its mass concentration was 1000 μg/mL,the relative activity of Hela cells decreased to 65.82%.

关 键 词：Ru-Mn配合物 多吡啶 合成 抗肿瘤活性 晶体结构 

分 类 号：O621.3[理学—有机化学]